



medlab

MEDLAB CLINICAL LIMITED

ABN: 51 169 149 071

**APPENDIX 4E (RULE 4.3A)
PRELIMINARY FINAL REPORT
FOR THE YEAR ENDED 30 JUNE 2017**

RESULTS FOR ANNOUNCEMENT TO THE MARKET

CURRENT REPORTING PERIOD:
PREVIOUS CORRESPONDING PERIOD:

Financial Year Ended 30 June 2017
Financial Year Ended 30 June 2016

KEY INFORMATION	2017 \$	Up/Down	Movement
Revenue from ordinary activities	4,446,533	Up	70%
(Loss) from ordinary activities after tax attributable to members	(3,657,644)	Down	5%
Net (loss) attributable to members	(3,657,644)	Down	5%
	2017 \$		2016 \$
Dividends proposed	Nil		Nil
Net tangible assets per security	0.017		0.012

During the period, Medlab has made significant advances in both research and the nutraceutical business. A summary of recent achievements are:

- Two clinical trials about to start, using our two different cannabis based medicines (NanaBis™ and NanaBidial™).
- Ethics and TGA approvals for commencement of our cannabis human trials.
- Commencement of two clinical trials, for depression using Medlab's NRGBiotic™ and cholesterol management.
- Several human trials completed.
- Testing of wider application of our patented delivery system, NanoCelle™, under way.

Nutritional sales have grown basically from a standing start and we've more than doubled the previous year's turnover. Medlab now have 24 nutritional products on the market with 6 to 8 more in the pipeline. As well we have just completed a marketing agreement with Heritage Brands Ltd for the provision of a "Nutraceutical Fighting Brand" for the front of shop in retail pharmacies. Also, recent research shows that Medlab's Nanocelle™ delivery systems adds significant potential to medicines and nutraceuticals.

Finally, our NRGBiotic™ nutraceutical product has been used in successful depression trials and is currently in the Australian and New Zealand markets (Patent pending). Given that the Australian government spent \$564 million last year on subsidised depression prescriptions alone, we remain very positive about the future growth of not only our NRGBiotic™ product but also our other nutraceutical products and our delivery system (Nanocelle™).

For a more detailed report of the company's operations, refer to the Chairman and CEO Reports in the 2017 Annual Report.

This report should be read in conjunction with the consolidated financial report of Medlab Clinical Limited for the year ended 30 June 2017 which has been audited by ESV Accounting and Business Advisors. An unqualified opinion has been issued by the auditor.



Sean Hall
Managing Director
Dated this 31st day of August 2017
